Objective: To describe the incidence of rapid kidney function decline (RKFD), and stage 3 chronic kidney disease (CKD) in HIV-1-infected adults initiated on tenofovircontaining antiretroviral therapy.
Introduction
Tenofovir disoproxil fumarate (TDF), a nucleotide analogue reverse transcriptase inhibitor, is widely used in high, middle, and low-income countries around the world as part of combination antiretroviral therapy (ART) in the treatment of HIV [1] and is arguably the most valuable drug currently available in our armamentarium against this dreaded virus. The most recent ART guidelines published by the WHO recommend starting all eligible patients on a first-line regimen that includes TDF [2] . In addition to being used in treatment regimens, TDF has been recently approved in the United States as part of a preexposure prophylaxis regimen to prevent infection in people who are at risk for contracting HIV [3] .
In manufacturer-sponsored randomized clinical trials, TDF was found to have a good safety profile and low toxicity [4] [5] [6] [7] [8] . However, concerns have since been raised with regard to its potential nephrotoxicity. TDF is chemically similar to adefovir and cidofovir, both of which have clinically significant nephrotoxicity [9] . In addition, renal tubular toxicity was demonstrated in vitro and in animal models when high doses of TDF were administered. Furthermore, several cases of kidney dysfunction and/or acute kidney injury have been reported in TDF recipients [10] .
In contrast to industry-sponsored clinical trials, US and European observational cohort studies, retrospective reviews, and a meta-analysis by Hall and colleagues have reported kidney dysfunction associated with TDF use, have concluded that the reduction in estimated glomerular filtration rate (eGFR) using Cockcroft-Gault and the modification of diet in renal disease (MDRD) equations, is mild and of questionable clinical significance [11] [12] [13] [14] [15] . These reports are contradicted by a Veterans Health Administration observational study of over 10 000 patients which reported that TDF use was associated with higher risk for chronic kidney disease (CKD) and rapid decline in kidney function when compared with other drug regimens [16] .
Recent guidelines from the American HIV Medical Association and US Department of Health and Human
Services recommend biannual monitoring of kidney function in HIV-positive patients receiving a TDFcontaining regimen [17] . In resource-limited settings, the need for frequent laboratory tests may limit the use of TDF [18] . Most studies described above included patients who were primarily men and were conducted in resource-rich settings. Therefore, these studies have limited usefulness in policy decisions regarding monitoring in resource-limited settings, where the use of TDF is the greatest. Less than a handful of such studies have been conducted in sub-Saharan Africa, where the HIV disease burden is highest, more women are HIV-positive, treatment is initiated when the disease is more advanced, and resources are limited [18] [19] [20] . Furthermore, there are sketchy data on the incidence and predictors of kidney failure in patients receiving TDF-containing regimens in a 'real world' clinical setting in sub-Saharan Africa [21] [22] [23] . Given the prevalence of genetic susceptibility traits that place individuals of African descent at risk of kidney disease [24] , especially HIV-associated nephropathy [25] , more research is needed regarding the impact of TDF on kidney function; this information is crucial to guide clinicians, especially in view of the limited access to dialysis should patients develop kidney failure.
To that end, we conducted a retrospective cohort study of HIV-positive patients initiating TDF in South Africa. The aim of the study was to describe the incidence of kidney failure in patients receiving TDF-containing regimens in a 'real world' clinical setting in a public hospital in South Africa, a country with one of the highest burdens of HIV and the greatest numbers of patients on ART in the world.
Methods

Study design, settings, and population
A retrospective cohort study of HIV-positive individuals initiating ART-containing TDF was conducted at the outpatient Infectious Diseases Clinic (IDC) at Tygerberg Academic Hospital in Cape Town, South Africa. All patients in the cohort were ART-naive HIV-positive adults who attended the IDC, between September 2010 and May 2013. Ethics committee approval for the study was obtained from Stellenbosch University and the University of Pittsburgh. All patients who received TDF and had a baseline serum creatinine measurement along with at least one follow-up creatinine measurement were included in the analysis ( Fig. 1 ).
Data collection and laboratory analyses
Data were extracted from the IDC Microsoft Access Database which was created using a standardized data collection form following each patient visit. Missing data, incomplete data, and additional demographic and/or baseline information were abstracted from patient charts and laboratory results. Laboratory results for patients that were transferred to outside clinics following initiation of therapy were verified, and additional data on current ART regimen and patient weight at time of serum creatinine result were obtained from patient charts at these clinics, when available. The laboratory at Tygerberg Hospital performed the serum creatinine tests using an isotope dilution mass spectrometry traceable calibration method to standardize measurements.
Variables
Baseline variables collected included age, sex, height, weight, CD4 þ T-cell count, hepatitis B virus surface antigen status, diagnosis of diabetes or hypertension (determined by whether patient was on medication(s) for the condition), and preexisting kidney disease (determined by recorded diagnosis of kidney failure and/or at least one abnormal serum creatinine result based on local normal laboratory values).
Quantitative variables eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula [26] and the four-variable MDRD [27] for standardized creatinine. Our primary analyses used eGFR based on the CKD-EPI formula, and the results were confirmed with the MDRD eGFR. For each patient, we estimated the rate of change (slope) of eGFR over time using two approaches: the least squares approach and the Bayesian approach. Long-term kidney function was evaluated in two ways: rapid kidney function decline (RKFD) and incident stage 3 CKD. Patients were classified as having RKFD if the estimated rate of kidney function decline exceeded 3 ml/min per year. We defined incident stage 3 CKD as the development of an eGFR less than 60 ml/ min/1.73 m 2 during follow-up among patients who had an eGFR greater than or equal to 60 min per 1.75 m 2 at baseline.
Statistical analysis
We used the Bayesian model simulations to estimate the posterior probability of RKFD for each patient and summarized the distribution of these probabilities with a histogram. We compared mean differences in baseline characteristics between patients who had RKFD and those who did not using the t-test, or the rank-sum tests when the data were skewed. We compared differences in proportions between two groups using x 2 tests. We performed logistic regression and Cox proportional hazard models to examine the associations between baseline demographic, clinical characteristics with the risk of RKFD and incidence of stage 3 CKD, respectively. Time to incident stage 3 CKD was calculated and described using the Kaplan-Meier survival curve. For both models, bivariate analyses were used to investigate the unadjusted (crude) associations between each baseline or clinical characteristics and the risk of RKFD and incidence of stage 3 CKD.
Multivariable analyses were used to determine variables independently associated with the risk of RKFD and incidence of Stage 3 CKD. Variables with P-values less than 0.2 in the bivariate analyses were included in the multivariate model. We adjusted for patient's age and sex, irrespective of bivariate association. The results of the logistic regression and Cox proportional hazard models were presented as odds ratio (ORs) and hazard ratios (HRs), respectively, with 95% confidence intervals (CIs). The proportionality assumption was confirmed by loglog plots and Schoenfeld residuals [28] . In the adjusted model, age, baseline eGFR, and history of preexisting kidney disease were significantly, independently associated with RKFD ( (Table 3 ).
Discussion
In this study of HIV-infected South Africans who initiated TDF-containing antiretroviral regimens, the great majority of individuals had negative eGFR slopes, and over half developed RKFD and only 2% developed stage 3 CKD during a median follow-up of approximately 30 and 54 weeks, respectively. The factors associated with greater likelihood of RKFD included older age, female sex, and lower baseline eGFR. Our study quantifies the magnitude of risk for developing RKFD and stage 3 CKD among HIV-positive South African adults initiated on TDF-containing ART regimens.
Prior studies from sub-Saharan Africa have shown that kidney dysfunction is highly prevalent in HIV-infected individuals initiating ART. Studies set in Mwanza, Tanzania and Johannesburg, South Africa have shown that the prevalence of stage 2 CKD (eGFR 60-89 ml/ min per 1.73 m 2 ) is 30-40% whereas the prevalence of stage 3 CKD (eGFR 30-59 ml/min per 1.73 m 2 ) is estimated to be 5.2% to up to 25% [21, 22] . Much of the incident kidney dysfunction in TDF patients was related to preexisting renal disorder [21] .
Our findings of general decline in kidney function with TDF-treatment build upon these findings by evaluating a population in which the great majority of patients had preserved kidney function. Also, our results are consistent with those published by Mulenga and colleagues [31] . Among more than 60 000 patients who initiated ART in Zambia, those with abnormal baseline kidney function on TDF-containing regimens had a lower eGFR at 6 and 12 month of follow-up and were 2-3 times more likely to progress to advanced kidney dysfunction when compared with patients not on TDF regimens. In contrast, Kamkuemah and colleagues [32] demonstrated that the overall eGFR improved by 1.10 ml/min per 1.73 m 2 over 12 months following TDF initiation among 1092 HIV-infected individuals residing in Cape Town, South Africa. However, their study population was younger compared with our study population (mean 33 vs 38 years, respectively), and the disparate observations across studies are likely because of differences in study population characteristics. Also, Bygrave and colleagues [33] in Lesotho reported that among 933 HIV-infected initiating ART, 176 (18.9%) had a baseline creatinine clearance less than 50 ml/min and that renal function improved in all but only three of these patients. However, their operational data were highly limited by missing data and lack of key covariates for the analysis. Similarly, secondary analyses from the Development of Antiretroviral Therapy Trial conducted in Zambia, Uganda, and Zimbabwe, by Reid and colleagues documented that mild-to-moderate baseline renal impairment was relatively common, but these participants had the greatest increases in eGFR after starting ARTcontaining TDF. However, severe eGFR impairment was infrequent regardless of ART regimen and was generally related to intercurrent disease [19, 20] .
Of note, the overall rate of eGFR decline on TDF was more rapid than previously reported in studies from the United States [34] or Europe [35] . The discrepancy with data from developed countries may be because of other prevalent comorbidities (e.g., HIV-associated nephropathy, coinfection with Hepatitis B, or parasites such as Schistosoma haematobium and mansoni) which have been shown to be associated with kidney dysfunction in sub-Saharan Africa [25, [36] [37] [38] [39] [40] . Schistosomiasis has been associated with cystitis, obstructive uropathy, and immune-mediated glomerulonephritis, and may have contributed to the prevalent renal dysfunction [37, 40] . Therefore, one would not necessarily expect similar rate of eGFR decline in our study population compared with high-income settings [34, 35, 41] .
Our observation that a lower baseline kidney function was associated with higher risk of both RKFD and stage 3 CKD are consistent with several prior studies. Young and colleagues [15] Finally, our results demonstrate that older age was associated with higher odds of RKFD and higher risk of stage 3 CKD, whereas female sex was associated with higher risk of stage 3 CKD, as also reported by Msango and colleagues [22] in Tanzania. These observations may reflect the impact of age and sex on TDF circulating levels. Among HIV-infected women in the Women's Interagency HIV Study, each decade older of age was associated with a 1.23-fold increase in TDF area under the curve [42] . Although sex differences in TDF levels could not be assessed in the previous study, 10% incremental decreases in BMI were also associated with a 1.04-fold higher TDF area under the curve [42] . In a report by Gervasoni and colleagues as well as Msango et al. [22, 43] , low body mass index, particularly in HIVpositive women, was associated with higher risk of both TDF-related nephrotoxicity and bone toxicity.
Our study has important clinical and research implications. Although TDF-associated with CKD has been well described among HIV-positive patients in developed countries, there has been a relative dearth of studies in low 1226 AIDS 2016, Vol 30 No 8 and middle-income countries where limited resources present an impediment to both kidney function screening and monitoring. Our study, which utilized rigorous methodological approaches to assess longitudinal renal outcomes, represents one of the largest studies to date to assess TDF-related CKD risk in a resource-limited setting. Although the incidence of stage 3 CKD was small among TDF users, in a country like South Africa with the largest numbers of HIV-positive individuals on ART worldwide, the absolute numbers of patients with TDF nephrotoxicity is expected to be high. Therefore, with increasing use of TDF-containing regimens as firstline treatment for HIV infection in low and middle income countries, studies such as ours highlight an urgent need to assess future approaches to CKD monitoring and management in these settings. We identified sex as an important predictor for CKD among HIV-positive South Africans receiving TDF. Although sex differences in TDF exposure because of differences in BMI may explain our observations, additional studies are needed to evaluate for sex-based differences in other factors that may alter TDF-exposure such as treatment adherence. Future research should focus on whether or not simple diagnostic tools, such as the combination of serum creatinine-based GFR estimates and a urine dipstick, can cost-effectively identify patients at greatest risk of TDF-related toxicity [44] .
Although informative, our study has also several limitations. First, the follow-up time was relatively short.
Although most studies suggest that the greatest TDFrelated decline in kidney function occurs within the first year of initiation, longitudinal studies in sub-Saharan Africa are needed to better assess the impact of long-term TDF exposure on renal and bone health outcomes [44] . Secondly, we were unable to assess for proximal tubular injury that may occur despite preserved eGFR. To inform future guidelines for kidney disease screening and monitoring among HIV-infected individuals exposed to TDF, studies with more sensitive biomarkers for kidney injury are needed [44] . In addition, we defined stage 3 CKD based on a single eGFR estimate below 60 ml/min per 1.73 m 2 ; this may lead to greater misclassification of CKD status. Finally, this was a single-center study; therefore, our findings may not be generalizable to the remainder of sub-Saharan Africa that is highly variable with regard to access to care and kidney health assessments for HIV-infected individuals.
In conclusion, we showed that TDF was associated with both a higher likelihood of RKFD and stage 3 CKD among HIV-infected South Africans. Although the majority of individuals experienced RKFD in our study, only a small minority developed stage 3 CKD. Therefore, approaches that provide balanced allocation of limited resources toward screening and monitoring for kidney dysfunction and HIV disease management are critically needed in this setting.
